Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer.

Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T.

Mol Cancer Ther. 2019 Aug 8. pii: molcanther.0452.2019. doi: 10.1158/1535-7163.MCT-19-0452. [Epub ahead of print]

PMID:
31395690
2.

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.

Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K.

Oncogene. 2019 Feb;38(9):1398-1409. doi: 10.1038/s41388-018-0517-4. Epub 2018 Oct 9.

PMID:
30302022
3.

Hypomorphic A20 expression confers susceptibility to psoriasis.

Aki A, Nagasaki M, Malynn BA, Ma A, Kagari T.

PLoS One. 2017 Jun 28;12(6):e0180481. doi: 10.1371/journal.pone.0180481. eCollection 2017.

4.

Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis.

Inaba SI, Goto M, Tanaka-Takanaka K, Tanaka H, Tomisato W, Yuita H, Doi-Komuro H, Inoue R, Oshima K, Kagari T, Shimozato T, Izumi T.

Biopharm Drug Dispos. 2016 Dec;37(9):561-573. doi: 10.1002/bdd.2048. Epub 2016 Nov 14.

PMID:
27764535
5.

Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.

Tsuji T, Suzuki K, Nakamura T, Goto T, Sekiguchi Y, Ikeda T, Fukuda T, Takemoto T, Mizuno Y, Kimura T, Kawase Y, Nara F, Kagari T, Shimozato T, Yahara C, Inaba S, Honda T, Izumi T, Tamura M, Nishi T.

Bioorg Med Chem. 2014 Aug 1;22(15):4246-56. doi: 10.1016/j.bmc.2014.05.035. Epub 2014 May 24.

PMID:
24909680
6.

Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P₃-sparing S1P₁ agonists.

Asano M, Nakamura T, Sekiguchi Y, Mizuno Y, Yamaguchi T, Tamaki K, Shimozato T, Doi-Komuro H, Kagari T, Tomisato W, Inoue R, Yuita H, Oguchi-Oshima K, Kaneko R, Nara F, Kawase Y, Masubuchi N, Nakayama S, Koga T, Namba E, Nasu H, Nishi T.

Bioorg Med Chem Lett. 2012 May 1;22(9):3083-8. doi: 10.1016/j.bmcl.2012.03.067. Epub 2012 Mar 23.

PMID:
22487179
7.

Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.

Nakamura T, Asano M, Sekiguchi Y, Mizuno Y, Tamaki K, Nara F, Kawase Y, Yabe Y, Nakai D, Kamiyama E, Urasaki-Kaneno Y, Shimozato T, Doi-Komuro H, Kagari T, Tomisato W, Inoue R, Nagasaki M, Yuita H, Oguchi-Oshima K, Kaneko R, Nishi T.

Eur J Med Chem. 2012 May;51:92-8. doi: 10.1016/j.ejmech.2012.02.022. Epub 2012 Feb 25.

PMID:
22405291
8.

Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist.

Nakamura T, Asano M, Sekiguchi Y, Mizuno Y, Tamaki K, Kimura T, Nara F, Kawase Y, Shimozato T, Doi H, Kagari T, Tomisato W, Inoue R, Nagasaki M, Yuita H, Oguchi-Oshima K, Kaneko R, Watanabe N, Abe Y, Nishi T.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1788-92. doi: 10.1016/j.bmcl.2011.12.019. Epub 2012 Jan 2.

PMID:
22264485
9.

Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.

Nishi T, Miyazaki S, Takemoto T, Suzuki K, Iio Y, Nakajima K, Ohnuki T, Kawase Y, Nara F, Inaba S, Izumi T, Yuita H, Oshima K, Doi H, Inoue R, Tomisato W, Kagari T, Shimozato T.

ACS Med Chem Lett. 2011 Mar 2;2(5):368-72. doi: 10.1021/ml100301k. eCollection 2011 May 12.

10.

Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation.

Hu JK, Kagari T, Clingan JM, Matloubian M.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):E118-27. doi: 10.1073/pnas.1101881108. Epub 2011 Apr 25.

11.

[Survey of breast cancer patients on chemotherapy of generic drugs].

Tanaka T, Tanino H, Kagari T, Nojiri M, Hirai I, Hata K, Hayata A, Ikeda T.

Gan To Kagaku Ryoho. 2010 Dec;37(13):2887-90. Japanese. No abstract available.

PMID:
21235094
12.

Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3.

Nakao A, Ohkawa N, Nagasaki T, Kagari T, Doi H, Shimozato T, Ushiyama S, Aoki K.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4774-8. doi: 10.1016/j.bmcl.2010.06.122. Epub 2010 Jul 1.

PMID:
20637613
13.

Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 2.

Nakao A, Ohkawa N, Nagasaki T, Kagari T, Doi H, Shimozato T, Ushiyama S, Aoki K.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2435-7. doi: 10.1016/j.bmcl.2010.03.022. Epub 2010 Mar 10.

PMID:
20346666
14.

Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 1.

Nakao A, Ohkawa N, Nagasaki T, Kagari T, Doi H, Shimozato T, Ushiyama S, Aoki K.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4607-10. doi: 10.1016/j.bmcl.2009.06.094. Epub 2009 Jun 30.

PMID:
19596194
15.

Anti-type II collagen antibody accelerates arthritis via CXCR2-expressing cells in IL-1 receptor antagonist-deficient mice.

Kagari T, Tanaka D, Doi H, Iwakura Y, Shimozato T.

Eur J Immunol. 2007 Oct;37(10):2753-63. Erratum in: Eur J Immunol. 2007 Oct;37(10):2991.

16.
17.

Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis.

Tanaka D, Kagari T, Doi H, Shimozato T.

Immunology. 2006 Oct;119(2):195-202. Epub 2006 Jul 12.

18.

Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis.

Kagari T, Tanaka D, Doi H, Shimozato T.

J Immunol. 2003 Apr 15;170(8):4318-24.

20.
21.

Biochemical characterization of calsequestrin-binding 30-kDa protein in sarcoplasmic reticulum of skeletal muscle.

Kagari T, Yamaguchi N, Kasai M.

Biochem Biophys Res Commun. 1996 Oct 23;227(3):700-6.

PMID:
8885997

Supplemental Content

Loading ...
Support Center